Endologix Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Endologix

Access the complete profile.

Endologix Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	100 - 500Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	339112 Surgical & Medical Instrument Manufacturing 339113 Surgical Appliance & Supplies Manufacturing
Address	2 Musick Irvine, CA 92618

Note: Revenues for privately held companies are statistical evaluations.


Endologix's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Endologix's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Endologix is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Endologix Annual Revenue and Growth Rate

Endologix	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$100 - $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Endologix's revenues are gauged from an analysis of company filings.

Endologix's Income Statement (based on Industry Averages)

Endologix P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Endologix is developing and marketing. Endologix doesn't have any recent trademark applications, indicating Endologix is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
ENDOCROSS Medical devices, namely, synthetic stent grafts, endoscopic snares, needles for creating pathways in the body, delivery catheters and guidewires for treating vascular disease; stent grafts for improving blood flow in patients with peripheral artery disease	04/25/2022
DETOUR Medical procedures to treat vascular clots or occlusions, namely, a percutaneous femoral-popiteal bypass procedure; Medical services	04/07/2022
PQ BYPASS Medical devices, namely, stent grafts, snares, delivery catheters and guidewires for treating vascular disease; Stent grafts for improving blood flow in patients with peripheral artery disease	02/03/2022

See all trademarks and details in the Full Report.

Market Share of Endologix's Largest Competitors

A competitive analysis shows these companies are in the same general field as Endologix, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Endologix. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
INTERNATIONAL VITAMIN	Irvine, CA	100
NUTRA MANUFACTURING	Irvine, CA	41
METAGENICS	Aliso Viejo, CA	22
ENDOLOGIX	Irvine, CA	17
EVOLUS	Newport Beach, CA	12
NEW GENERATION WELLNESS	Irvine, CA	8

Future Competition: Endologix's Fastest Growing Competitors

These companies are in the same general field as Endologix and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)